Pfizer, BioNTech sign deal with Eurofarma to boost vaccine supply in Latin America

The big picture: "Per the agreement, Eurofarma will obtain drug product from facilities in the U.S., and manufacturing of finished doses will commence in 2022," the companies said.

• At full operational capacity, more than 100 million finished doses are expected to be produced annually, they added.
• These doses will be exclusively distributed through Latin America, adding to the vaccine supply from initiatives like COVAX or individual country donations.

What they're saying: “Everyone – regardless of financial condition, race, religion or geography – deserves access to lifesaving COVID-19 vaccines,” Pfizer CEO Albert Bourla said in a statement

• “Our new collaboration with Eurofarma expands our global supply chain network to another region – helping us continue to provide fair and equitable access to our COVID-19 vaccine," he added.
• “At such a difficult time as this one, being able to share this news fills us with pride and hope. Eurofarma is about to turn 50 years old and signing this collaboration in the production of the COVID-19 vaccine represents another milestone in our trajectory," Maurízio Billi, president of Eurofarma, added.